CHU Dijon Bourgogne
Dijon, 21000, France
Location status: Recruiting
Recruiting
NCT Number: NCT06905106
POlycythemia, Proteins and ErYthropoiesis
Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Persons who have given their non-opposition
Patients with polycythemia:
- haemoglobin value > 16 g/dl female or > 16.5 g/dl male
- with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary [cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...)
Patients control:
- persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of < 16 g/DL for women and < 16.5 g/DL for men
Exclusion criteria
- Person subject to a measure of legal protection (guardianship, tutorship)
- Person subject to a court order
- Pregnant, parturient or nursing woman
- Incapable of expressing consent
- Minor
Treatment and study plan
Collection of tube bottoms from blood samples taken in the clinic
BiologicalCollection of tube bottoms from blood samples taken in the clinic
Primary outcomes
-
Measurement of various proteins involved in the regulation of erythropoiesis
Time frame: at baseline
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Centre Hospitalier Universitaire Dijon
Other
Registry information
Acronym: POPEYE
Important dates
- Study start
- 2024
- Primary completion
- 2028
- Study completion
- 2028
- First posted
- Apr 1, 2025
- Registry last updated
- Apr 1, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Genomic of CONgenital Sideroblastic Anemias
NCT07459816
Anemia, Erythropoiesis
Amiens, France
View Trial Details
Completed
Effects of Intermittent Hypoxia Training With Iron Supplementation on Red Blood Cells and Iron Levels in Trained Athletes
NCT07720960
Erythropoiesis, Hypoxia
Elche, Alicante, Spain
View Trial Details